Altimmune Inc [ALT] stock prices are up 14.51% to $10.18 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ALT shares have gain 11.75% over the last week, with a monthly amount drifted -23.34%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, March 2024, Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results. In a post published today on Yahoo Finance, Body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass.
From an analyst’s perspective:
Altimmune Inc [NASDAQ: ALT] stock has seen the most recent analyst activity on January 24, 2024, when Goldman initiated its Neutral rating and assigned the stock a price target of $13. Previously, Goldman downgraded its rating to Neutral on March 22, 2023, and dropped its price target to $6. On December 01, 2022, Goldman initiated with a Buy rating and assigned a price target of $20 on the stock. H.C. Wainwright initiated its recommendation with a Buy and recommended $35 as its price target on June 02, 2021. Guggenheim started tracking with a Buy rating for this stock on February 11, 2021, and assigned it a price target of $36. In a note dated December 14, 2020, Jefferies initiated an Buy rating and provided a target price of $25 on this stock.
The stock price of Altimmune Inc [ALT] has been fluctuating between $2.09 and $14.84 over the past year. Currently, Wall Street analysts expect the stock to reach $31.2 within the next 12 months. Altimmune Inc [NASDAQ: ALT] shares were valued at $10.18 at the most recent close of the market. An investor can expect a potential return of 206.48% based on the average ALT price forecast.
Analyzing the ALT fundamentals
The Altimmune Inc [NASDAQ:ALT] reported sales of 0.43M for trailing twelve months, representing a surge of 133.64%. Gross Profit Margin for this corporation currently stands at -76.88% with Operating Profit Margin at -196.03%, Pretax Profit Margin comes in at -207.62%, and Net Profit Margin reading is -203.67%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.51 and Total Capital is -0.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.18 points at the first support level, and at 8.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.84, and for the 2nd resistance point, it is at 11.50.
Altimmune Inc [ALT] reported earnings per share of -$0.33 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.43/share, meaning a difference of $0.1 and a surprise factor of 23.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.39 per share as compared to estimates of -$0.42 per share, a difference of $0.03 representing a surprise of 7.10%.
Ratios To Look Out For
It’s worth pointing out that Altimmune Inc [NASDAQ:ALT]’s Current Ratio is 17.25. As well, the Quick Ratio is 17.25, while the Cash Ratio is 11.13. Considering the valuation of this stock, the price to sales ratio is 1272.03, the price to book ratio is 3.71.
Transactions by insiders
Recent insider trading involved Drutz David, Director, that happened on Aug 15 ’23 when 300.0 shares were purchased.
